{"id":32101,"date":"2024-08-09T17:26:46","date_gmt":"2024-08-09T21:26:46","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=32101"},"modified":"2024-08-25T20:00:31","modified_gmt":"2024-08-26T00:00:31","slug":"marco-ruella-md","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/marco-ruella-md","title":{"rendered":"Marco Ruella, MD"},"content":{"rendered":"\n<p>When Hodgkin Lymphoma (HL) comes back after treatment, it is very difficult to treat. CAR T immunotherapy is a novel type of cancer treatment that re-educates patients\u2019 immune cells to recognize and kill tumor cells. Unfortunately, CAR T therapy often fails because of the very unwelcoming environment around cancer cells that inhibits CAR T cells. Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the HL environment. He proposes that if BTLA could be removed from CAR T cells, this treatment might work better. <\/p>\n\n\n\n<p>Therefore, he has created a new kind of CAR T treatment, which he calls TRENTA-CAR T, that targets CD30, a molecule found on the HL cells that do not have BTLA. When testing TRENTA-CAR T in laboratory models, it worked better at fighting cancer than standard therapies. The main goal is now to move this new TRENTA-CAR T treatment to HL patients. In this project, Dr. Ruella will get the necessary approvals to start the trial. This study is positioned to change the outlook for people with HL that has recurred or has not responded to treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">BTLA-deleted anti-CD30 chimeric antigen receptor T cells for relapsed or refractory Hodgkin lymphoma: toward clinical translation<\/h3>\n\n\n\n<p>University of Pennsylvania | Lymphoma | 2024<\/p>\n","protected":false},"excerpt":{"rendered":"<p>When Hodgkin Lymphoma (HL) comes back after treatment, it is very difficult to treat. CAR T immunotherapy is a novel type of cancer treatment that re-educates patients\u2019 immune cells to recognize and [&hellip;]<\/p>\n","protected":false},"featured_media":32102,"template":"","tax_cancer_type":[355],"tax_grant_type":[485],"tax_award_year":[741],"tax_institutions":[487],"tax_location_states":[488],"class_list":["post-32101","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"CRI CLIP Investigator","quote":"","scientist_last_name":"Ruella","show_on_landing":true,"scientist_publish_until":"20280831"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marco Ruella, MD - Cancer Research Institute<\/title>\n<meta name=\"description\" content=\"Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the Hodgkin Lymphoma environment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marco Ruella, MD - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the Hodgkin Lymphoma environment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-26T00:00:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"672\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md\",\"name\":\"Marco Ruella, MD - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg\",\"datePublished\":\"2024-08-09T21:26:46+00:00\",\"dateModified\":\"2024-08-26T00:00:31+00:00\",\"description\":\"Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the Hodgkin Lymphoma environment.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg\",\"width\":500,\"height\":672},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marco Ruella, MD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marco Ruella, MD - Cancer Research Institute","description":"Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the Hodgkin Lymphoma environment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md","og_locale":"es_ES","og_type":"article","og_title":"Marco Ruella, MD - Cancer Research Institute","og_description":"Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the Hodgkin Lymphoma environment.","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md","og_site_name":"Cancer Research Institute","article_modified_time":"2024-08-26T00:00:31+00:00","og_image":[{"width":500,"height":672,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md","name":"Marco Ruella, MD - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg","datePublished":"2024-08-09T21:26:46+00:00","dateModified":"2024-08-26T00:00:31+00:00","description":"Dr. Ruella identified a marker, BTLA, that is expressed in immune cells that drives their inhibition in the Hodgkin Lymphoma environment.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg","width":500,"height":672},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/marco-ruella-md#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Marco Ruella, MD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2024\/08\/Ruella-Marco.jpeg","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/32101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/32102"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=32101"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=32101"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=32101"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=32101"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=32101"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=32101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}